Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37548629.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1736.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The influence of sex on immunotherapy response in patients with non-small cell lung cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17β-estradiol/ERα/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options. See related article by Anobile et al., p. 3958.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms